While not quite on a par with Mel Brooks' 2,000 Year-Old Man, this volume reports on some folks who've been around for a long time. Contributors to 15 papers indicate that such longevity rarely existed prior to the 19th century. Appends statistical data on predicting age distribution, and documentation of a family's exceptional longevity. Lacks an index. Distributed in the US by ISBS. Annotation copyrighted by Book News, Inc., Portland, OR

States that the number of genuine long-livers is exploding and a substantial proportion of new-borns in developed countries may survive to celebrate their 100th birthday. This book examines the storied realms of exceptional longevity.

Does human mortality after age 110 continue to rise, level off, or start to decline? This book describes a concerted, international research effort undertaken with the goal of establishing a database that allows the best possible description of the mortality trajectory beyond the age of 110. The International Database on Longevity (IDL) is the result of this ongoing effort. The IDL contains exhaustive information on validated cases of supercentenarians (people 110 years and older) and allows unbiased estimates of mortality after age 110. The main finding is remarkable: human mortality after age 110 is flat at a probability of death of 50% per year. The sixteen chapters of this book discuss age validation of exceptional longevity, data on supercentenarians in a series of countries, structure and contents of the IDL, and statistical analysis of human mortality after age 110. Several chapters include short accounts of specific supercentenarians that add life to demographic research.

Key research in the world’s largest aging population – in China – has fed into this important new work, which aims to answer questions critical to older people worldwide. These include: is the period of disability compressing or expanding with increasing life expectancy and what factors are associated with these trends in the recent decades? And is it possible to realize morbidity compression with a prolongation of the life span in the future? Essential reading for gerontologists.

Old-age survival has considerably improved in the second half of the twentieth century. Why has such a substantial extension of human lifespan occurred? How long can we live? In this book, these fundamental questions are explored by experts from diverse fields. They report on recent cutting-edge studies about essential issues of human longevity and social factors of long survival in old age.

This book demonstrates different statistical techniques for analyzing health-related data as well as providing new techniques for forecasting and/or projecting the incidence of diseases/disorders. It presents information on a variety of health related issues from the developed and developing world. Featuring cutting edge research from distinguished applied demographers and public health specialists, the book bridges the gap between theory and research. Each chapter provides methods and materials that can be used to conduct further research aimed at promoting public health issues. This book is intended for public health professionals, health policy makers, social epidemiologists, administrators, researchers, and students in the fields of applied demography and public health who are interested in exploring the potential of ground-breaking research or who want to further develop their existing research techniques. It complements another volume in the Applied Demography Series, Applied Demography and Public Health (Springer, 2013), which describes how applied demographic techniques can be used to help address public health issues.

Bolle Willum Luxdorph, who lived from 1716-1788, was the first Dane known to have studied the phenomenon of old age. Luxdorph was a high-ranking Danish civil servant, a leader of the Danish Chancellery, as well as a scholar and poet. In the last years of his life, Luxdorph created an art collection of paintings of older people ("long-livers"). The exact date at which Luxdorph began taking an interest in the phenomenon of old age is not known, but it must have happened sometime in the late 1770s. At this point, Luxdorph began systematically collecting data concerning very old people (i.e. persons who had reached the age of 80 and over). This book examines Luxdorph's collection, which has a triple-source value in terms of the history of art, the history of civilization, and the history of science. Both the reconstruction and the availability of the collection hold specific contemporary and general importance for: the illustration of very old men and women, the development of research on ageing, and the associated socio-cultural topics. Moreover, the collection represents an encyclopedic interest, the passion to collect, and the origin of science-orientated collections, as they became characteristic in 18th-century Europe.

Paleodemography is the field of enquiry that attempts to identify demographic parameters from past populations (usually skeletal samples) derived from archaeological contexts, and then to make interpretations regarding the health and well-being of those populations. However, paleodemographic theory relies on several assumptions that cannot easily be validated by the researcher, and if incorrect, can lead to large errors or biases. In this book, physical anthropologists, mathematical demographers and statisticians tackle these methodological issues for reconstructing demographic structure for skeletal samples. Topics discussed include how skeletal morphology is linked to chronological age, assessment of age from the skeleton, demographic models of mortality and their interpretation, and biostatistical approaches to age structure estimation from archaeological samples. This work will be of immense importance to anyone interested in paleodemography, including biological and physical anthropologists, demographers, geographers, evolutionary biologists and statisticians.

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

More than 2.3 million Americans are now age 85 and older, and the population total in this age group is steadily expanding. This book brings together leading researchers to review current knowledge about the demography, health, epidemiology and social status of the oldest old. From discussions of the impact of Alzheimer's disease to an examination of changing social and medical policies, this book provides much needed information about this often neglected but growing group.The special problems attendant to information gathering among the oldest old, such as interviews and research, are also addressed. Special intercultural perspectives inform chapters on "The Black Oldest Old", and "Institutional Long-term Care from an International Perspective". This is essential reading for gerontologists, public health professionals, epidemiologists, and policy makers. The book's broad scope enlarges our understanding of the current needs of the oldest old, and indicates areas of public concern.